WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007095618) BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/095618    International Application No.:    PCT/US2007/062241
Publication Date: 23.08.2007 International Filing Date: 15.02.2007
IPC:
A61K 31/353 (2006.01), A61K 31/357 (2006.01), A61K 31/36 (2006.01), A61P 25/06 (2006.01)
Applicants: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, Belgium, B-2340 Beerse (BE) (For All Designated States Except US).
SMITH-SWINTOSKY, Virginia L. [US/US]; (US) (For US Only)
Inventors: SMITH-SWINTOSKY, Virginia L.; (US)
Agent: JOHNSON, Philip S.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US)
Priority Data:
60/773,764 15.02.2006 US
11/674,021 12.02.2007 US
Title (EN) BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE
(FR) UTILISATION DE DÉRIVÉS DE SULFAMIDE À NOYAU HÉTÉROCYCLIQUE BENZOFUSIONNÉ POUR LE TRAITEMENT DE LA MIGRAINE
Abstract: front page image
(EN)The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment and / or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent.
(FR)La présente invention concerne un procédé de traitement ou de prévention de la migraine, comprenant l'administration à un sujet nécessitant un tel traitement d'une quantité thérapeutiquement efficace d'un ou plusieurs nouveaux dérivés de sulfamide à noyau hétérocyclique benzofusionné de formule (I) et de formule (II) ainsi que défini ici. Elle concerne un procédé de traitement ou de prévention de la migraine qui comprend une monothérapie et, en variante, une co-thérapie avec au moins un agent antimigraineux.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)